{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:49:32Z","timestamp":1788608972821,"version":"build-2803163510"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2021,1,11]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>In phase II and III trials, anifrolumab, a human monoclonal antibody that binds type I interferon receptor subunit 1, has shown efficacy in adults with moderate to severe SLE. We evaluated the safety and tolerability of anifrolumab using data pooled from these trials to more precisely estimate the rate and severity of adverse events (AEs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were pooled from patients receiving monthly intravenous anifrolumab 300\u2009mg or placebo in MUSE, TULIP-1 and TULIP-2. Key safety endpoints included percentages and exposure-adjusted incidence rates (EAIRs) of patients who experienced AEs, serious AEs (SAEs), AEs leading to discontinuation and AEs of special interest.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During treatment, 86.9% of patients receiving anifrolumab 300\u2009mg (n=459) experienced AEs (\u22651) versus 79.4% receiving placebo (n=466), and 4.1% versus 5.2% experienced an AE leading to discontinuation of investigational product. SAEs (\u22651) were experienced by 11.8% and 16.7% of patients receiving anifrolumab and placebo, respectively (EAIR risk difference (95%\u2009CI) \u22127.2 (\u221212.5 to \u20131.9)), including lupus exacerbations classified as SAEs (1.5% and 3%, respectively). Infections occurred in 69.7% and 55.4% of patients receiving anifrolumab and placebo, respectively; difference in reported rates was driven by herpes zoster (HZ) and mild and moderate respiratory (excluding pneumonia) infections. The risk of HZ was increased with anifrolumab versus placebo (6.1% vs 1.3%, respectively; EAIR risk difference (95% CI) 5.4 (2.8 to 8.4)); most HZ events were mild or moderate, cutaneous and resolved without treatment discontinuation. Serious infections occurred in 4.8% and 5.6% of patients receiving anifrolumab and placebo, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this pooled analysis of 925 patients with moderate to severe SLE, monthly intravenous anifrolumab 300\u2009mg was generally well tolerated over 52 weeks with an acceptable safety profile. Anifrolumab was associated with an increased incidence of HZ and respiratory tract infections and lower reported rate of SLE worsening as SAEs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2020-000464","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T19:01:12Z","timestamp":1613588472000},"page":"e000464","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":89,"title":["Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01438489","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02446912","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02446899","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Raj","family":"Tummala","sequence":"first","affiliation":[{"name":"Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Abreu","sequence":"additional","affiliation":[{"name":"BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Pineda","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Alex","family":"Michaels","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubana N","family":"Kalyani","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Furie","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Zucker School of Medicine at Hofstra\/Northwell, Great Neck, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F","family":"Morand","sequence":"additional","affiliation":[{"name":"Centre for Inflammatory Disease, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"2025091511583492000_8.1.e000464.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205171"},{"key":"2025091511583492000_8.1.e000464.2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/rheumatology\/kex412","article-title":"Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014)","volume":"57","author":"Jorge","year":"2018","journal-title":"Rheumatology"},{"key":"2025091511583492000_8.1.e000464.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210973"},{"key":"2025091511583492000_8.1.e000464.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2017.09.013"},{"key":"2025091511583492000_8.1.e000464.5","doi-asserted-by":"crossref","first-page":"kew475","DOI":"10.1093\/rheumatology\/kew475","article-title":"The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: a Danish nationwide population-based cohort study","volume":"56","author":"Hermansen","year":"2017","journal-title":"Rheumatology"},{"key":"2025091511583492000_8.1.e000464.6","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1234-1"},{"key":"2025091511583492000_8.1.e000464.7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22575"},{"key":"2025091511583492000_8.1.e000464.8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fmed.2018.00161","article-title":"Systemic lupus erythematosus in primary care: an update and practical messages for the general practitioner","volume":"5","author":"Gergianaki","year":"2018","journal-title":"Front Med"},{"key":"2025091511583492000_8.1.e000464.9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2017.1327353","article-title":"The evolving concept of SLE comorbidities","volume":"13","author":"Gonz\u00e1lez","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2025091511583492000_8.1.e000464.10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/keaa478","article-title":"The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis","volume":"60","author":"Pego-Reigosa","year":"2021","journal-title":"Rheumatology"},{"key":"2025091511583492000_8.1.e000464.11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001247"},{"key":"2025091511583492000_8.1.e000464.12","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2014-000066"},{"key":"2025091511583492000_8.1.e000464.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/347520","article-title":"Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review","volume":"2013","author":"Oglesby","year":"2013","journal-title":"Int J Rheumatol"},{"key":"2025091511583492000_8.1.e000464.14","first-page":"316","article-title":"Therapy side effects in systemic lupus erythematosus","volume":"44","author":"Popa","year":"2018","journal-title":"Curr Health Sci J"},{"key":"2025091511583492000_8.1.e000464.15","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007810"},{"key":"2025091511583492000_8.1.e000464.16","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2019-000336"},{"key":"2025091511583492000_8.1.e000464.17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40521-020-00242-2","article-title":"Hypersensitivity reactions to biologicals: from bench to bedside","volume":"7","author":"Akarsu","year":"2020","journal-title":"Curr Treat Options Allergy"},{"key":"2025091511583492000_8.1.e000464.18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an Anti-Interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025091511583492000_8.1.e000464.19","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025091511583492000_8.1.e000464.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196"},{"key":"2025091511583492000_8.1.e000464.21","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9599-2"},{"key":"2025091511583492000_8.1.e000464.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089"},{"key":"2025091511583492000_8.1.e000464.23","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025091511583492000_8.1.e000464.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207654"},{"key":"2025091511583492000_8.1.e000464.25","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312469259"},{"key":"2025091511583492000_8.1.e000464.26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/21645515.2018.1514228","article-title":"Herpes zoster vaccination in systemic lupus erythematosus: the current status","volume":"15","author":"Mok","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"2025091511583492000_8.1.e000464.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215882"},{"key":"2025091511583492000_8.1.e000464.28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew406"},{"key":"2025091511583492000_8.1.e000464.29","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(19)30105-5","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort study","volume":"2","author":"Apostolopoulos","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025091511583492000_8.1.e000464.30","doi-asserted-by":"crossref","unstructured":"Chatham WW , Furie R , Saxena A , et al . Long\u2010term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase 2 open\u2010label extension study. Arthritis Rheumatol 2020.doi:10.1002\/art.41598","DOI":"10.1002\/art.41598"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2020-000464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T18:58:43Z","timestamp":1757962723000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2020-000464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,2,17]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/lupus-2020-000464"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2020-000464","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}